Post-market surveillance

Post-market surveillance identifies risks and performance problems that emerge when medical products are used by larger and more diverse populations. Preauthorization studies may be too small or too short to reveal rare adverse reactions, delayed effects, interactions, manufacturing defects, or problems associated with unusual clinical settings. The activity is broader than collecting adverse-event reports: regulators and manufacturers also examine product quality, labeling, clinical use, device failures, and patterns of off-label or incorrect use.

For medicines and vaccines, the discipline is closely associated with pharmacovigilance, which includes detecting, assessing, understanding, and preventing adverse effects or other drug-related problems.¹ For medical devices, surveillance addresses malfunctions, design limitations, usability problems, and whether a device continues to meet its intended performance. The central question is not simply whether an event occurred, but whether the product contributed to it and whether regulatory action is warranted.

Surveillance works by combining complementary evidence streams rather than relying on one reporting channel. These include spontaneous reports from clinicians, patients, and manufacturers; electronic health-record and insurance-claims analyses; disease and product registries; post-authorization safety studies; inspections; laboratory testing; complaints; and manufacturer trend analysis.

Signals are observations that merit evaluation, not proof of causation. Analysts consider the timing of exposure and event, alternative explanations, reporting rates, biological plausibility, comparator data, and whether the pattern is reproduced in independent datasets. Findings can lead to updated warnings, contraindications, restricted distribution, additional studies, changes in manufacturing or design, safety communications, recalls, suspension, or withdrawal. In the United States, device manufacturers may have obligations under the Medical Device Reporting system and, for certain products, formal postmarket surveillance studies.

Post-market surveillance is a shared responsibility among regulators, manufacturers, health professionals, patients, and health-care institutions. Manufacturers are generally expected to maintain risk-management and vigilance systems, investigate complaints, report qualifying events, and take corrective action; regulators assess signals and coordinate proportionate interventions.

Requirements differ by jurisdiction and product class. The European Union places medicines within a pharmacovigilance framework coordinated through national authorities and the European Medicines Agency, while the Medical Device Regulation requires manufacturers to operate post-market surveillance systems proportionate to device risk. ^{International standards seek compatible terminology and methods, but data-sharing remains complicated by different reporting rules, privacy laws, coding systems, product identifiers, and access to linked health records.}

Some of the most informative surveillance findings arise from weak signals and product-use context rather than dramatic isolated events. A cluster of complaints about a device model may reveal a packaging or usability defect; a medication signal may become visible only after exposure among older adults, pregnant people, or patients with kidney impairment. Underreporting, stimulated reporting after publicity, duplicate submissions, changing exposure levels, and incomplete clinical information can distort apparent frequencies, so spontaneous-report databases generally cannot provide reliable incidence rates by themselves.

Surveillance also includes benefits and performance. Regulators may examine whether a device performs as intended in ordinary practice, whether a vaccine's protection changes against circulating variants, or whether a medicine's real-world effectiveness differs across populations. Digital tools, distributed data networks, patient registries, and active surveillance can shorten the interval between a safety signal and its evaluation, but they do not remove the need for clinical review, transparent methods, and communication of uncertainty.¹

Pharmacovigilance

The science and activities concerned with detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems.

Safety signal

Information suggesting a new or changed causal relationship between a product and an event that requires further evaluation.

Spontaneous report

An unsolicited report of a suspected adverse event or product problem submitted by a health professional, patient, manufacturer, or other source.

Post-authorization safety study

A study conducted after authorization to obtain additional information about a medicine's safety or risks.